免疫检查点抑制剂在软组织肉瘤中的应用:现状与展望

Current status and prospect of immune checkpoint inhibitors in treatment of advanced soft tissue sarcoma

软组织肉瘤是一类少见的起源于间叶组织的除骨或软骨以外的恶性肿瘤,发病率低,但晚期转移患者通常缺乏有效的治疗手段,预后差,死亡率高。近年来,免疫检查点抑制剂(ICIs)在恶性肿瘤免疫治疗领域中取得了重要进展。在许多肿瘤中,ICIs有效改善了患者的预后,但在软组织肉瘤中,虽然有相关应用探索,却尚未获得高级别循证医学证据。本文总结了ICIs在软组织肉瘤临床治疗中的进展,包括ICIs单药及与其他治疗手段的联合使用,探讨了ICIs在未来软组织肉瘤治疗中的研究方向,希望为相关临床工作者提供参考。

Soft tissue sarcomas(STS) are a rare group of mesenchymal malignancies except bone or cartilage, with a low incidence rate. Patients with advanced STS have limited treatment options, poor prognosis and high mortality. Recently, immune checkpoint inhibitors(ICIs) have made great breakthroughs in the field of tumor therapy, greatly improving the prognosis of patients with various malignancies. However, efficacy of ICIs in the treatment of STS remains unravelled. This review summarizes the role of the ICIs in various sets of advanced STS treatment and provides future research directions, hoping to serve as a reference for clinicians.